What Is De Novo Sequencing And How Does It Work? Key Facts

De novo sequencing is a DNA sequencing method used to read the genetic code of an organism for the first time, without using any existing reference genome as a guide. Unlike resequencing, which compares new DNA data to a known map, de novo sequencing builds that map from scratch by assembling millions of short DNA reads into long, continuous sequences called contigs. This process allows researchers to discover new genes, mutations, and entire genomes that have never been documented before.

How Does De Novo Sequencing Work at a Technical Level?

De novo sequencing starts by extracting DNA from a sample and breaking it into small fragments. These fragments are then sequenced using high-throughput machines, which read the order of nucleotide bases — A, T, C, and G — in each piece. A single run can generate billions of these short reads, each typically 150 to 300 base pairs long.

The real challenge is assembly. Because no reference genome exists, the computer must overlap the ends of these fragments like puzzle pieces. Algorithms look for identical sequences at the ends of different reads and stitch them together into longer sequences called contigs. Gaps between contigs are filled using paired-end reads, which come from both ends of a known fragment size, or long-read sequencing technologies that produce reads tens of thousands of base pairs long.

Modern de novo sequencing often combines short reads from Illumina machines with long reads from PacBio or Oxford Nanopore platforms. This hybrid approach gives both high accuracy and long-range continuity. The final output is a draft genome that can be refined through additional sequencing and manual curation.

What Makes De Novo Sequencing Different From Resequencing?

Resequencing is like reading a book when you already have a copy. You compare the new text to the original and note differences. De novo sequencing is like writing the book from scratch after hearing it told aloud. You have no reference, so every base must be placed correctly through computational assembly.

This difference matters because resequencing is faster, cheaper, and more accurate for organisms with well-characterized genomes. For example, sequencing a human genome for medical purposes typically uses resequencing against the human reference genome. De novo sequencing is reserved for organisms that lack a reference genome, such as newly discovered bacteria, plants, or rare animal species.

The National Institutes of Health notes that de novo assembly requires significantly more computational power and sequencing depth than resequencing. Coverage depth — how many times each base is read — typically needs to be 30x to 50x or higher for a reliable de novo assembly, compared to 10x to 15x for resequencing.

What Types of Organisms Are Studied With De Novo Sequencing?

De novo sequencing is used across the tree of life. Microbiologists apply it to sequence new bacterial and viral strains, especially those that cause emerging diseases. In 2020, researchers used de novo sequencing to assemble the genome of SARS-CoV-2 within weeks of its discovery, which enabled rapid vaccine development.

Botanists and agricultural scientists sequence crop plants like quinoa, cassava, and wild rice varieties to identify genes for drought tolerance, pest resistance, and nutritional content. Marine biologists use de novo sequencing on deep-sea organisms that cannot be cultured in a lab. Conservation geneticists sequence endangered species to understand population structure and genetic diversity.

Human genomics also uses de novo sequencing in specific cases. Researchers sequence individuals from isolated populations or ancient DNA samples where no close reference genome exists. The Human Pangenome Project, launched in 2019, uses de novo assembly of hundreds of human genomes to create a more diverse reference that captures genetic variation missed by the single reference genome used since 2001.

What Are the Main Challenges of De Novo Sequencing?

The biggest challenge is assembling repetitive DNA regions. Repetitive sequences — long stretches of identical or nearly identical base pairs — confuse assembly algorithms because short reads from different copies look the same. This leads to broken contigs, misassemblies, and gaps in the final genome.

Heterozygosity is another problem. In diploid organisms like humans, each chromosome pair contains two slightly different copies. De novo assemblers must distinguish between true sequence variation and sequencing errors, which is difficult without a reference. Some assemblers collapse both copies into one consensus sequence, losing half the genetic information.

Computational requirements are substantial. Assembling a single mammalian genome can require terabytes of RAM and weeks of processing time on high-performance computing clusters. The cost has dropped dramatically — a human genome can now be de novo assembled for under $10,000 — but this remains expensive compared to resequencing, which costs around $1,000 per genome.

A 2023 study in Nature Methods compared 14 different de novo assemblers and found that no single tool worked best across all genome types. The choice of assembler depends on read length, coverage depth, and the organism’s genome complexity. This means researchers must test multiple assemblers to find the best one for their specific data.

What Does Research on De Novo Sequencing Show About Its Accuracy?

Accuracy in de novo sequencing is measured by contig N50 — the length at which half the assembled genome is in contigs of that size or larger. For bacterial genomes, modern assemblers routinely achieve N50 values exceeding the entire genome length, meaning the assembly is complete. For mammalian genomes, N50 values of 50 to 100 million base pairs are common, with the remaining gaps concentrated in centromeres and other repetitive regions.

The Telomere-to-Telomere Consortium achieved the first truly complete human genome in 2022 by combining ultra-long Oxford Nanopore reads with accurate Illumina short reads. This assembly closed all gaps in the human genome, including the highly repetitive centromeres and ribosomal DNA arrays that had remained unfinished since 2001. This milestone demonstrated that de novo sequencing can produce complete genomes when sufficient read length and coverage are used.

Research published in Genome Biology found that hybrid assemblies — combining short and long reads — reduced assembly errors by 10 to 100-fold compared to short-read-only approaches. The error rate for base calls in long-read technologies has dropped from 15% in early PacBio systems to under 1% in current models, making de novo sequencing increasingly reliable for clinical and research applications.

What Are Common Misconceptions About De Novo Sequencing?

One widespread misconception is that de novo sequencing produces a perfect genome on the first attempt. In reality, even the best assemblies contain errors and gaps. The Telomere-to-Telomere human genome required years of additional sequencing and manual curation to achieve completeness. Most de novo assemblies are considered “draft” genomes that improve over time with additional data.

Another myth is that de novo sequencing is only for exotic or non-model organisms. While it is essential for those cases, de novo assembly is increasingly used to improve reference genomes for well-studied species. The current human reference genome, GRCh38, contains regions that were assembled de novo from individuals of diverse ancestry to reduce bias toward the original European-derived reference.

Some people believe that longer reads always produce better assemblies. Long reads help span repetitive regions, but they have higher error rates than short reads. The best results come from combining both read types. A 2022 benchmark in Nature Communications showed that hybrid assemblies outperformed both long-read-only and short-read-only approaches across 10 different bacterial genomes.

• De novo sequencing does not replace resequencing — each method has distinct use cases.
• Draft genomes are useful for many applications but should not be treated as complete.
• Long reads alone do not guarantee a better assembly than a hybrid approach.
• Computational cost remains a barrier for labs without access to high-performance computing.
• Assembly quality varies significantly between different software tools and parameter settings.

What Are the Practical Applications of De Novo Sequencing Today?

In medicine, de novo sequencing is used to identify structural variants — large insertions, deletions, and rearrangements — that are missed by standard resequencing methods. The 100,000 Genomes Project in the UK used de novo assembly to detect disease-causing structural variants in patients with rare genetic disorders who had negative results from conventional testing.

Agricultural biotechnology companies sequence crop wild relatives using de novo methods to find genes that could improve domesticated varieties. The African Orphan Crops Consortium, for example, has de novo sequenced over 100 indigenous African food crops to support breeding programs for nutritional improvement and climate adaptation.

Forensic science uses de novo sequencing to analyze DNA from crime scenes when the perpetrator’s genome is not in any database. Microbial forensics applies the same approach to trace the origin of pathogens in bioterrorism investigations or disease outbreaks.

Environmental DNA studies rely on de novo sequencing to identify organisms from soil, water, or air samples without needing to culture them. This approach, called metagenomics, has revealed thousands of previously unknown microbial species and is reshaping our understanding of microbial diversity on Earth.